Head-to-Head: which drug works better for psoriatic arthritis in the real world?

NCT ID NCT07386717

Completed Disease control Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 70 people with psoriatic arthritis to compare two drug types: upadacitinib and IL-17 inhibitors. Researchers tracked joint and skin symptoms over 24 weeks in routine care. The goal is to see which works better in real life, helping doctors personalize treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: upadacitinib and interleukin-17 inhibitors
What this could lead to: If this study shows one drug works better in real life, it could help doctors choose the best treatment for each person with psoriatic arthritis.
What could go wrong: This is a small, completed observational study, not a large trial. Results may not apply to everyone, and the 24-week follow-up is too short to see long-term effects or rare side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERLEUKIN-17 INHIBITORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTERLEUKIN-17 INHIBITORS PSORIATIC ARTHRITIS UPADACITINIB

Contacts and locations

Locations

Peking University First Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.